Article Text

Download PDFPDF
Extended initial course of prednisolone did not improve clinical outcomes in steroid-sensitive nephrotic syndrome
  1. David Wands1,
  2. Ben C Reynolds2
  1. 1 Gastroenterology, Hepatology and Clinical Nutrition, Royal Hospital for Children, Glasgow, UK
  2. 2 Paediatric Renal Unit, Royal Hospital for Children, Glasgow, UK
  1. Correspondence to Dr David Wands, Gastroenterology, Hepatology and Clinical Nutrition, Royal Hospital for Children Glasgow, Glasgow G51 4TF, UK; david.wands{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Study design: Double-blind, parallel-group, randomised, placebo-controlled trial.

Setting and patients: 237 patients with steroid-sensitive idiopathic nephrotic syndrome aged 1–14 years recruited from 125 UK tertiary nephrology centres and district general hospitals.1

Intervention: Randomisation to standard 8-week course of prednisolone (60 mg/m2 for 4 weeks, then 40 mg/m2 alternate days for 4 weeks, total dose 2240 mg/m2) or an extended 16-week course (60 mg/m2 for 4 weeks, then 10 mg/m2 wean weekly for 12 weeks, total dose 3150 mg/m2).

Primary outcome: Time to first relapse.

Secondary outcomes: Relapse rate, use of alternative immunosuppression, …

View Full Text


  • Contributors DW wrote the initial paper. BCR edited and revised the manuscript.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.